RAIR has access to highly-sought real world evidence (“RWE”) sourced through a non-exclusive data license agreement with an NHS Trust. The data that RAIR can call on currently reflects a population of c.1m people generating over 100k new episodes a year.
OculAIR KE (knowledge engineering) uses many different data sets, including real world data, in order to abstract relationships between seemingly unrelated pieces of information.
The ability to identify and validate new clinical hypotheses, digitally, may help identify new drug targets; identify new uses for existing drugs or combinations of drugs; and develop clinical decision support algorithms.
OculAIR BI (bio informatics) combines RAIR’s data assets with a best-in-class, scalable, serverless, informatics solution.
OculAIR BI provides clients with the opportunity to extract machine learning-powered insights from the OculAIR RWE which help them to make better decisions at every stage of the development pathway from bench to bedside.
OculAIR ML (machine learning) combines RAIR’s data assets and a best-in-class machine learning platform to convert a hypotheses, often derived from OculAIR BI or OculAIR KE, into a specific service or product such as a clinical decision support algorithm.
With offices at tech centres across Europe, Future Processing has expertise in the field of medical software development; big data engineering and machine/deep learning with particular specialisation in the development of advanced medical and image segmentation algorithms.
Grakn is the knowledge graph engine to organise complex networks of data and making it queryable, by performing knowledge engineering. Grakn provides the knowledge foundation for cognitive and intelligent (e.g. AI) systems, by providing an intelligent language for modelling, transactions and analytics.
It is estimated that the annual economic burden of vision loss and vision disorders in adults costs the UK economy around £22 billion per year and in the US economy $ 139 billion.
RAIR's medical retina data lake includes two of the largest ophthalmic indications: diabetic macular oedema and neovascular (or “Wet”) age-related macular degeneration (nAMD).
The increased incidence of chronic eye disease, including diabetes and nAMD, has placed the healthcare system under significant financial and clinical pressure:
Diabetic macular oedema (DMO) and Age-related macular degeneration (AMD) account for 20% of the 1.8m new NHS presentations and 8m consultations each year and represent the major
The increased incidence of chronic eye disease, including diabetes and nAMD, has placed the healthcare system under significant financial and clinical pressure:
Diabetic macular oedema (DMO) and Age-related macular degeneration (AMD) account for 20% of the 1.8m new NHS presentations and 8m consultations each year and represent the major causes of vision loss.
However, in the UK:
67% of eye units are using locums;
85% of units are reliant on waiting list initiatives to clear backlogs and 4.2m patients are waiting to start treatment.
Anti-VEGF therapy is the first-line drug treatment for DMO and AMD. However, while far more effective than the alternatives, anti-VEGF drugs are ineffective or partially effective in 41-64% of treated patients, and in 4.5-8.8% of treated patients their eyesight actually deteriorates.
Nonetheless, anti-VEGF therapies constituted the 2nd a
Anti-VEGF therapy is the first-line drug treatment for DMO and AMD. However, while far more effective than the alternatives, anti-VEGF drugs are ineffective or partially effective in 41-64% of treated patients, and in 4.5-8.8% of treated patients their eyesight actually deteriorates.
Nonetheless, anti-VEGF therapies constituted the 2nd and 8th highest individual drug costs across the entire NHS in 2018 and, in the US, anti-VEGF therapy accounts for c.12% of Medicare Part B drug spending.
The burden of administering frequent intravitreal injections on healthcare human resources is also considerable, with each patient requiring several treatments a year, administered by a trained practitioner, most often a consultant ophthalmologist.
...acuité is also a commercial and legal framework which serves as a "clearing house" between between researchers, AI developers and providers of anonymised health data insights.